Stay updated on PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial
Sign up to get notified when there's something new on the PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial page.

Latest updates to the PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial page
- Check4 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedRevision: v3.4.2 is displayed, replacing the previous v3.4.1. This appears to be a backend/UI maintenance update with no visible changes to study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedMinor version update from Revision: v3.4.0 to v3.4.1 with no visible changes to core content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check47 days agoChange DetectedShow glossary and minor copy changes (including a Revision: v3.4.0 note and capitalization tweaks) were added; these changes do not affect study data or core functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision label on the page updated from v3.3.3 to v3.3.4.SummaryDifference0.1%

- Check83 days agoChange DetectedFooter now shows Revision: v3.3.3. The HHS Vulnerability Disclosure link and the previous Revision: v3.3.2 entry were removed.SummaryDifference0.1%

Stay in the know with updates to PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial page.